Do Bleeding-Control gels help in kidney cancer surgery?
NCT ID NCT07232927
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested whether adding special agents (FloSeal® or Surgicel®) to standard suturing during partial nephrectomy reduces bleeding and other complications. 150 patients with localized kidney tumors were randomly assigned to one of three groups. The main outcomes were bleeding, urine leaks, and cancer-free margins.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- FloSeal® (gelatin-thrombin matrix) and Surgicel® (oxidized regenerated cellulose)
- What this could lead to
- If successful, this could show that using these agents during kidney tumor removal reduces bleeding and other complications, improving recovery.
- What could go wrong
- This is a completed trial, so results are available. However, it is a single-surgeon study with 150 patients, so findings may not apply to all hospitals or surgeons.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
150 people
The number who actually took part.
- Started
-
Jan 2023
- Finished
-
Dec 2024
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patients aged 18 years or older. * Diagnosed with localized renal mass (clinical stage T1a-T1b) suitable for partial nephrectomy. * Adequate preoperative renal function to undergo surgery. * Signed informed consent obtained prior to study enrollment. * Undergoing open, laparoscopic, or robotic partial nephrectomy performed by the same experienced surgeon. Exclusion Criteria: * Patients with solitary kidney or bilateral renal tumors. * History of previous renal surgery on the same kidney. * Evidence of metastatic disease or locally advanced (≥T2) renal tumors. * Coagulopathy, bleeding disorders, or ongoing anticoagulant therapy that cannot be discontinued. * Active urinary tract infection or systemic infection. * Known allergy or hypersensitivity to gelatin or oxidized cellulose components. * Patients who decline participation or withdraw consent. * Incomplete perioperative data or loss to follow-up.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Hemostatic agents are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Ankara University Faculty of Medicine, Department of Urology
Ankara, Ankara, 06590, Turkey (Türkiye)
More trials for these conditions
Other studies related to the condition(s) this trial covers.